{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:19:30Z","timestamp":1790054370263,"version":"4.0.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"CV Therapeutics","award":["MERLIN-TIMI 36"],"award-info":[{"award-number":["MERLIN-TIMI 36"]}]},{"name":"Critical Diagnostics"},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["RC1HL099692"],"award-info":[{"award-number":["RC1HL099692"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>We investigated the prognostic performance of ST2 with respect to cardiovascular death (CVD) and heart failure (HF) in patients with non\u2013ST-elevation acute coronary syndrome (NSTE-ACS) in a large multinational trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Myocytes that are subjected to mechanical stress secrete ST2, a soluble interleukin-1 receptor family member that is associated with HF after STE-ACS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We measured ST2 with a high-sensitivity assay in all available baseline samples (N = 4426) in patients enrolled in the Metabolic Efficiency With Ranolazine for Less Ischemia in the Non\u2013ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36), a placebo-controlled trial of ranolazine in NSTE-ACS. All events, including cardiovascular death and new or worsening HF, were adjudicated by an independent events committee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Patients with ST2 concentrations in the top quartile (&amp;gt;35 \u03bcg\/L) were more likely to be older and male and have diabetes and renal dysfunction. ST2 was only weakly correlated with troponin and B-type natriuretic peptide. High ST2 was associated with increased risk for CVD\/HF at 30 days (6.6% vs 1.6%, P &amp;lt; 0.0001) and 1 year (12.2% vs 5.2%, P &amp;lt; 0.0001). The risk associated with ST2 was significant after adjustment for clinical covariates and biomarkers (adjusted hazard ratio CVD\/HF 1.90, 95% CI 1.15\u20133.13 at 30 days, P = 0.012; 1.51, 95% CI 1.15\u20131.98 at 1 year, P = 0.003), with a significant integrated discrimination improvement (P &amp;lt; 0.0001). No significant interaction was found between ST2 and ranolazine (Pinteraction = 0.15).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>ST2 correlates weakly with biomarkers of acute injury and hemodynamic stress but is strongly associated with the risk of HF after NSTE-ACS. This biomarker and related pathway merit further investigation as potential therapeutic targets for patients with ACS at risk for cardiac remodeling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1373\/clinchem.2011.173369","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T00:49:54Z","timestamp":1321577394000},"page":"257-266","source":"Crossref","is-referenced-by-count":132,"title":["Role of ST2 in Non\u2013ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial"],"prefix":"10.1093","volume":"58","author":[{"given":"Payal","family":"Kohli","sequence":"first","affiliation":[{"name":"TIMI Study Group, and"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P","family":"Bonaca","sequence":"first","affiliation":[{"name":"TIMI Study Group, and"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kakkar","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastacia Y","family":"Kudinova","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M","family":"Scirica","sequence":"first","affiliation":[{"name":"TIMI Study Group, and"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Sabatine","sequence":"first","affiliation":[{"name":"TIMI Study Group, and"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina A","family":"Murphy","sequence":"first","affiliation":[{"name":"TIMI Study Group, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"first","affiliation":[{"name":"TIMI Study Group, and"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T","family":"Lee","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Morrow","sequence":"first","affiliation":[{"name":"TIMI Study Group, and"},{"name":"Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,1,1]]},"reference":[{"key":"2020022705222052700_B1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.164.2.2008120","article-title":"Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation","volume":"164","author":"Oshikawa","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2020022705222052700_B2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4049\/jimmunol.173.1.145","article-title":"A novel therapy of murine collagen-induced arthritis with soluble T1\/ST2","volume":"173","author":"Leung","year":"2004","journal-title":"J Immunol"},{"key":"2020022705222052700_B3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1006\/bbrc.2001.5090","article-title":"Identification of human ST2 protein in the sera of patients with autoimmune diseases","volume":"284","author":"Kuroiwa","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"2020022705222052700_B4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1007\/s00134-004-2184-x","article-title":"Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma","volume":"30","author":"Brunner","year":"2004","journal-title":"Intensive Care Med"},{"key":"2020022705222052700_B5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2249.2007.03441.x","article-title":"The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders","volume":"149","author":"Barksby","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"2020022705222052700_B6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cytogfr.2004.02.004","article-title":"T1\/ST2: an IL-1 receptor-like modulator of immune responses","volume":"15","author":"Trajkovic","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"2020022705222052700_B7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"2020022705222052700_B8","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1161\/01.CIR.0000038705.69871.D9","article-title":"Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction","volume":"106","author":"Weinberg","year":"2002","journal-title":"Circulation"},{"key":"2020022705222052700_B9","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1161\/01.CIR.0000127958.21003.5A","article-title":"Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction","volume":"109","author":"Shimpo","year":"2004","journal-title":"Circulation"},{"key":"2020022705222052700_B10","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/CIRCULATIONAHA.107.728022","article-title":"Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction","volume":"117","author":"Sabatine","year":"2008","journal-title":"Circulation"},{"key":"2020022705222052700_B11","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ahj.2011.03.025","article-title":"Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP","volume":"161","author":"Dhillon","year":"2011","journal-title":"Am Heart J"},{"key":"2020022705222052700_B12","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"2020022705222052700_B13","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","article-title":"Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"2020022705222052700_B14","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.ahj.2006.01.004","article-title":"Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial","volume":"151","author":"Morrow","year":"2006","journal-title":"Am Heart J"},{"key":"2020022705222052700_B15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cca.2009.08.010","article-title":"Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma: the Presage ST2 assay","volume":"409","author":"Dieplinger","year":"2009","journal-title":"Clin Chim Acta"},{"key":"2020022705222052700_B16","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2009.09.068","article-title":"B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial","volume":"55","author":"Morrow","year":"2010","journal-title":"J Am Coll of Cardiol"},{"key":"2020022705222052700_B17","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/eurheartj\/ehm355","article-title":"Universal definition of myocardial infarction","volume":"28","author":"Thygesen","year":"2007","journal-title":"Eur Heart J"},{"key":"2020022705222052700_B18","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ahj.2010.02.022","article-title":"ST2 and mortality in non-ST-segment elevation acute coronary syndrome","volume":"159","author":"Eggers","year":"2010","journal-title":"Am Heart J"},{"key":"2020022705222052700_B19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"2020022705222052700_B20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1432-1327.1999.00615.x","article-title":"Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells","volume":"264","author":"Iwahana","year":"1999","journal-title":"Eur J Biochem"},{"key":"2020022705222052700_B21","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J Clin Invest"},{"key":"2020022705222052700_B22","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"2020022705222052700_B23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20071868","article-title":"IL-33 reduces the development of atherosclerosis","volume":"205","author":"Miller","year":"2008","journal-title":"J Exp Med"},{"key":"2020022705222052700_B24","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jacc.2008.07.042","article-title":"Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure","volume":"52","author":"Rehman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2020022705222052700_B25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/CIRCHEARTFAILURE.108.833707","article-title":"Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea","volume":"2","author":"Shah","year":"2009","journal-title":"Circ Heart Fail"},{"key":"2020022705222052700_B26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","article-title":"Identification of serum soluble ST2 receptor as a novel heart failure biomarker","volume":"107","author":"Weinberg","year":"2003","journal-title":"Circulation"},{"key":"2020022705222052700_B27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacc.2007.05.014","article-title":"Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study","volume":"50","author":"Januzzi","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2020022705222052700_B28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1373\/clinchem.2007.096560","article-title":"Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure","volume":"54","author":"Mueller","year":"2008","journal-title":"Clin Chem"},{"key":"2020022705222052700_B29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.amjcard.2010.09.011","article-title":"Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction","volume":"107","author":"Manzano-Fernandez","year":"2011","journal-title":"Am J Cardiol"},{"key":"2020022705222052700_B30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11897-010-0005-9","article-title":"ST2: a novel remodeling biomarker in acute and chronic heart failure","volume":"7","author":"Shah","year":"2010","journal-title":"Curr Heart Fail Rep"},{"key":"2020022705222052700_B31","first-page":"S808","article-title":"Prognostic utility of serial measurements of a novel biomarker ST2 in STEMI patients treated with primary PCI","volume-title":"Circulation","author":"Grabowski","year":"2009"},{"key":"2020022705222052700_B32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2009.08.047","article-title":"Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction","volume":"55","author":"Weir","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2020022705222052700_B33","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.immuni.2005.10.004","article-title":"An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor","volume":"23","author":"Dinarello","year":"2005","journal-title":"Immunity"},{"key":"2020022705222052700_B34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/dbio.1995.1063","article-title":"Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo","volume":"168","author":"Rossler","year":"1995","journal-title":"Dev Biol"},{"key":"2020022705222052700_B35","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1073\/pnas.95.12.6930","article-title":"T1\/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function","volume":"95","author":"Lohning","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020022705222052700_B36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCHEARTFAILURE.109.873240","article-title":"Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling","volume":"2","author":"Seki","year":"2009","journal-title":"Circ Heart Fail"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/58\/1\/257\/32658700\/clinchem0257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/58\/1\/257\/32658700\/clinchem0257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T05:22:44Z","timestamp":1582780964000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/58\/1\/257\/5620660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,1]]},"published-print":{"date-parts":[[2012,1,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2011.173369","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,1,1]]},"published":{"date-parts":[[2012,1,1]]}}}